Monday, May 10

AstraZeneca: European Medicines Agency recognizes link between vaccine and “very rare” cases of thrombosis

The European Medicines Agency (EMA) confirmed, Wednesday, April 7, what one of its experts had announced in the Italian press the day before: in some cases, – “Very rare », Hammered Emer Cooke, the executive director of the agency -, the injection of AstraZeneca vaccine against the Covid-19 can cause atypical blood clots, associated with a low level of blood platelets, likely to engage the vital prognosis. But “Its benefits remain far greater than the risks it incurs”, she continued.

Understand: You are more likely to die from Covid-19 if you catch it than from a blood clot caused by injecting a dose of AstraZeneca. But when we ask the AEM whether this conclusion is also valid for the population of women under 60, who are the first affected by the appearance of dangerous side effects, its experts say they cannot respond.

Article reserved for our subscribers Read also European Medicines Agency official adds to confusion over AstraZeneca vaccine

The AEM is also not able, at this stage, to define risk factors – whether it is the age, the gender, or the medical history of the people having undergone thromboembolic events – and thus does not make any assessment. specific recommendations related to the use of the AstraZeneca vaccine. “It is plausible that the appearance of these clots after vaccination with AstraZeneca is linked to an immune response to the vaccine”, commented Emer Cooke.

“Worrisome” but “rare” phenomena

European scientists have carefully analyzed the sixty-two cases of cerebral venous sinus thrombosis and the twenty-four cases of splanchnic vein thrombosis, which had been recorded as of March 22 (since then the number of cases has increased but the AEM ensures that this does not change its conclusions), and caused eighteen deaths, for a population of twenty-five million people vaccinated with AstraZeneca in continental Europe and the United Kingdom. They will continue their assessment.

The AEM also asked the Anglo-Swedish laboratory to conduct additional studies and entrusted teams of researchers from two universities, in Rotterdam and Utrecht (Netherlands), to explore the subject further. .

“The use of the vaccine for vaccination campaigns must also be analyzed with regard to the pandemic situation and the other vaccines available” countries, also found it useful to clarify the EAJ. While the variants are spreading at high speed and Europeans do not yet have enough doses to vaccinate their citizens at all costs, there is, in any case, no question of depriving themselves of AstraZeneca. “The Covid-19 kills thousands of people every day in Europe”, repeated Emer Cooke.

You have 43.56% of this article to read. The rest is for subscribers only.

www.lemonde.fr

Leave a Reply

Your email address will not be published. Required fields are marked *